



## DIACCURATE INTRODUCES ITS WORLD-LEADING SCIENTIFIC ADVISORY BOARD

- 6 independent world-renowned experts in the fields of immunology, immunotherapy and oncology
  - Chaired by Professor Tasuku HONJO, 2018 NOBEL PRIZE in Physiology or Medicine

Paris, France, July 8<sup>th</sup> 2021

DIACCURATE, a French biotechnology company that develops sole-in-class therapeutics in immunotherapy, oncology and infectiology today announced the formation of its Scientific Advisory Board (SAB). Composed of 6 independent world-leading experts in the fields of basic and translational immunology, lipid metabolism, oncology and immunotherapy DIACCURATE's SAB is chaired by Professor Tasuku HONJO, Kyoto University's Institute for Advanced Study (KUIAS), awarded by the 2018 NOBEL PRIZE in Physiology or Medicine for his discovery of "immune checkpoint inhibitors", a key step in the history of cancerology.

**Dr. Dominique BRIDON, CEO of DIACCURATE**, commented: *"We feel honored to have gathered this world-renowned group of experts in our newly formed Scientific Advisory Board around Prof. Jacques THÈZE, CSO and Scientific co-Founder of DIACCURATE". He added: "We look forward to building on their exceptional knowledge and complementary experience in immunology, immunotherapy and oncology to progress our highly original and ambitious pipeline towards the clinic."*

*"Cancer treatment has seen a revolution in immunotherapy. Extensive research to which my lab has contributed has brought to light the importance of cytotoxic CD8 T cells in the antitumor immune response, giving rise to current immune checkpoint inhibitors. But the role of CD4 T cells in this response had so far remained overlooked", said Prof. Tasuku HONJO, Deputy Director-General of KUIAS and Chairman of DIACCURATE's SAB. He explained: "Recent findings have demonstrated the key contribution of CD4 T cells to clinical efficacy of PD-L1/PD-1 blockade therapies. The developments undertaken at DIACCURATE to boost CD4 T cells functionality could represent a major step towards improving immunotherapy."*

**Prof. Christoph HUBER, co-founder of the mRNA vaccine pioneer BioNTech, board member of the International Association of Cancer Immunotherapy and member of DIACCURATE's SAB**, added: *"As we have seen once again with the COVID-19 pandemic, vaccines are an invaluable immunotherapy tool to prevent and treat diseases that affect the immune system. It has been well known for over a century in the field of infectious diseases, it is also becoming an evidence in the field of oncology, and strategies like that of DIACCURATE that potentiate CD4 T cells response are expected to further improve the efficacy and the profile of vaccines"*.

**Dr. Bernard MALISSEN, Founder and Director of the Center for Immunophenomics, team leader and former Director of the Centre d'Immunologie de Marseille Luminy and member of DIACCURATE's SAB**, concluded: *"Intricate biological networks control*



*physiological and pathologic processes and revolve around biological switches. By integrating incoming signals and determining the downstream pathways that need to be activated, they constitute key “decision makers”. DIACCURATE has laid solid foundations to take on the challenge of targeting such biological switches, which are of tremendous importance in various pathological contexts, including cancer and infectious diseases”.*

## Scientific Advisory Board



### **Prof. Tasuku HONJO, MD, Chairman**

Prof. HONJO is Deputy Director-General and Distinguished Professor of Kyoto University's Institute for Advanced Study (Japan). He was first known for his discovery of activation-induced cytidine deaminase (AID), the enzyme responsible for class switch recombination and somatic hypermutation in B lymphocytes.

He later identified a number of key molecules involved in immune regulation, including his seminal discovery of PD-1 (programmed cell death protein 1), a receptor at the surface of certain immune cells that acts as a brake that contains the immune response. He further demonstrated that PD-1 inhibition would unleash this brake, stimulating the inherent ability of the immune system to attack tumor cells and establishing an entirely new principle for cancer therapy. This discovery earned him the NOBEL PRIZE in Physiology and Medicine in 2018, which he shared with Prof. James P. ALLISON.



### **Prof. Christopher HUBER, MD**

Prof. HUBER is co-founder of BioNTech, Emeritus Professor of Medicine at the Medical School of the Johannes Gutenberg University in Mainz (Germany), co-founder and Head of the Supervisory Board at the Cluster for Individualized Immune Intervention (CI-3) and board member of the International Association of Cancer Immunotherapy (CIMT), among other roles.

He has over 40 years of clinical and research experience in hematology, oncology, stem cell transplantation and tumor immunology.



**Prof. Jim NORMAN**

Prof. NORMAN is Professor of Cell Science at the University of Glasgow (United Kingdom), Senior research group leader and Deputy Director at Cancer Research UK's Beatson Institute. His group studies the mechanisms through which integrins and other cellular adhesion receptors control how cancers grow and form metastases. In particular, he most recently focuses on the endocytosis and recycling of integrins and how the molecular machinery responsible for these intracellular trafficking events drives cancer cell migration and invasion.



**Prof. Paolo PARINI, MD**

Prof. PARINI is Professor, Senior Consultant, Director of Research, Education, Development and Innovation at the Karolinska Institute and Karolinska University Hospital, Stockholm (Sweden), and visiting Professor at the University of Milano (Italy). He specializes in the study of lipid and lipoprotein metabolism in the context of cardiometabolic diseases.

Prof. PARINI's research particularly focuses on sex-related and species-related differences in these metabolic pathways, with an emphasis on their regulation at the molecular level. By combining the study of *in vitro* systems, mouse models and patients, his group has a unique expertise in translational research activities in the field of metabolic disorders.



**Dr. Bernard MALISSEN**

Dr. MALISSEN is the Founder and Director of the Centre for Immunophenomics (CIPHE), team leader at the Centre d'Immunologie de Marseille Luminy (CIML, Marseille, France). He directed the CIML from 1995 to 2005. He is a member of the French Academy of Sciences, an Honorary Member of the American Association of Immunologists and a Fellow of the European Research Council.

Dr. MALISSEN pioneered in the 80's the use of gene transfer approaches to dissect the function of molecules involved in T cell functions (MHC and TCR). His lab has also extended its interest to dendritic cells and macrophages, a research area where it disentangled the functional complexity of the dendritic cells found in tissue parenchymas.

He has more recently turned to high-throughput "omics" approaches that simultaneously measure large numbers of parameters, and combines them with genetic screens designed to further the understanding of T cell functions under normal and pathological conditions.



**Prof. Jean-Pierre DELORD, MD**

Prof. DELORD is Director of the Centre de Lutte Contre le Cancer Claudius Regaud (Toulouse, France), where he heads the Early Phase Trial programs, the Clinical Research Unit, the Pharmacology Laboratory and the Medical Oncology Department. He is also director of the Institut Universitaire du Cancer Toulouse-Oncopole (IUCT-O, France).

Prof. DELORD's research interests focus on the biology of ovarian cancer, head and neck cancer, the pharmacology of anticancer drugs, and the relationship between the tumor micro-environment and malignant cells. He is involved in preclinical programs for the development of new compounds from basic research to early clinical phases, pharmacokinetic, pharmacodynamic studies and "First in Human" trials.

He is a member of several scientific boards in the biotech and pharmaceutical industries, with valuable expertise in pre-clinical phases of development. He is a national expert of the Minister of Research and Industry.

**DIACCURATE**

DIACCURATE is a late preclinical stage biotechnology company that invests the new frontiers of immunotherapy and oncology, firstly CD4 immunotherapy and targeted chemotherapy. At the forefront of translational medicine, these sole-in-class drug candidates target incurable diseases: refractory acute myeloid leukemia, pancreatic cancer and AIDS. DIACCURATE is conducting 3 proprietary development programs and expects to start its first clinical trial by 2022.

DIACCURATE is supported by a high-level management team led by Dr. Dominique BRIDON and world-class Board of Directors and Scientific Advisory Board chaired by Dr. Philippe POULETTY, CEO of TRUFFLE, and Prof. Tasuku HONJO, 2018 Nobel Prize in Medicine.

For more information, visit [www.diaccurate.com](http://www.diaccurate.com) and follow [@DiaccurateTx](https://twitter.com/DiaccurateTx)

**TRUFFLE CAPITAL**

Created in 2001, TRUFFLE CAPITAL is an independent European Venture Capital company, specialising in life sciences (MedTech and Biotech) and in breakthrough IT technologies (FinTech and InsurTech). The mission of TRUFFLE CAPITAL is to help the creation and development of young innovating companies, capable of becoming tomorrow's leaders.

Chaired by Patrick KRON and led by Dr. Philippe POULETTY et Bernard-Louis ROQUES, co-founders and CEOs, TRUFFLE CAPITAL has raised over €1.1 billion since its inception and helped over 70 companies in the digital technology and life sciences sectors. In 2019, TRUFFLE CAPITAL announced having raised almost €400 million in new institutional funds, including €250 million for new BioMedTech investments.

For more information, visit [www.truffle.com](http://www.truffle.com) and follow [@trufflecapital](https://twitter.com/trufflecapital)

**Contacts****DIACCURATE****Dominique BRIDON, CEO**

+33 6 73 25 12 18

[dominique.bridon@diaccurate.com](mailto:dominique.bridon@diaccurate.com)

**ATCG-PARTNERS**

Marie PUVIEUX

+33 (0)6 10 54 36 72

Jérôme MARINO

+33 6 11 56 98 91

[presse@atcg-partners.com](mailto:presse@atcg-partners.com)

**TRUFFLE CAPITAL****DGM CONSEIL**

+33 1 40 70 11 89

Thomas DE CLIMENS

Quentin HUA

Olivier LABESSE

[thomasdeclimens@dgm-conseil.fr](mailto:thomasdeclimens@dgm-conseil.fr)